A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3-Reference-Cited by-同舟云学术

A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3

Published:2018-04-02 Issue:4 Volume:10 Page:636-650
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Bednenko Janna¹^ORCID,Harriman Rian²,Mariën Lore³,Nguyen Hai M.⁴,Agrawal Alka¹,Papoyan Ashot¹,Bisharyan Yelena¹,Cardarelli Joanna¹,Cassidy-Hanley Donna⁵,Clark Ted¹⁵,Pedersen Darlene⁶,Abdiche Yasmina⁷,Harriman William⁶,van der Woning Bas³,de Haard Hans³,Collarini Ellen⁶,Wulff Heike⁴,Colussi Paul¹

Affiliation:

1. TetraGenetics Inc, Arlington, Massachusetts, USA

2. Department of Immunology, Crystal Bioscience, Emeryville, California, USA

3. argenx, Zwijnaarde, Belgium

4. Department of Pharmacology, University of California, Davis, California, USA

5. Department of Immunology and Microbiology, Cornell University, Ithaca, New York, USA

6. Ligand Pharmaceuticals, San Diego, California, USA

7. Carterra Inc, Salt Lake City, Utah, USA

Funder

Juvenile Diabetes Research Foundation International-PI Paul Colussi, PhD,

Publisher

Informa UK Limited